UnitedHealthcare respiratory multiplex coverage update

Coverage Criteria — Respiratory Multiplex Testing

Outpatient panels (6+ targets)

Not medically necessary when ALL of the following are met:

Outpatient large multiplex panels: Respiratory pathogen panel testing of six or more targets in an outpatient setting is unproven and not medically necessary.>=6 targets

Coverage rationale: insufficient evidence of efficacy for outpatient use.

Clinical use criteria

Coverage and use considerations informed by guideline consensus and evidence:

Hospitalized or high-risk patients: Multiplex molecular respiratory/pneumonia panels are appropriate or recommended for hospitalized patients (including ICU), and for immunocompromised patients (hematology/oncology, transplant) and pediatric patients with underlying illness.

Supported by ASM and IDSA guidance and joint professional reports.

Outpatients: Routine outpatient nucleic acid–based testing for noninfluenza viral pathogens is generally not suggested; testing may be appropriate for outpatients with severe symptoms or who are at high risk for complications (e.g., older adults, immunocompromised).

Reflects ATS conditional recommendation and IDSA selective testing advice.

Interpretation caveats: Results require clinical correlation: negative panel results do not reliably exclude infection for all targets, and positive results may reflect colonization rather than active infection.

Performance varies by target and specimen type; positive agreement reported 16.7%–100% with negative agreement >90% in some studies; diagnostic stewardship recommended.

Respiratory pathogen panel testing that includes six or more targets performed in an outpatient setting is considered not medically necessary and is designated unproven due to insufficient evidence of efficacy for outpatient indications.

For adult outpatients with suspected community-acquired viral respiratory infection, the American Thoracic Society issues a conditional recommendation against routine nucleic acid–based testing of respiratory samples for viral pathogens other than influenza, citing very low–quality evidence; testing should be selective and guided by clinical context.

The coverage rationale identifies insufficient evidence that multiplex respiratory panels with ≥6 targets improve clinically meaningful outcomes in the outpatient setting. Because efficacy across intended outpatient indications is not established, these large panels are excluded from coverage as not medically necessary.

Clinical studies and guideline reviews show limited incremental benefit of broad multiplex testing for many outpatients. A retrospective outpatient study found that identification of influenza—but not noninfluenza viruses—was associated with reduced antibiotic prescribing, suggesting targeted influenza testing may suffice. Guideline panels (ATS; joint AMP/ASM/IDSA/PASCV statements) note variable performance across targets, risks of detecting colonization rather than infection, and recommend diagnostic stewardship when testing relatively healthy outpatients.

Covered Indications and Appropriate Use

When conventional testing fails or rapid pathogen identification is needed

Covered when ALL of the following are met:

When conventional testing fails: When conventional microbiological testing fails to identify a pathogen or is non-diagnostic for a suspected respiratory infection.

mNGS may identify pathogens missed by conventional methods; see Liu et al. (2024).

Rapid identification needed: When rapid or comprehensive pathogen identification is clinically necessary to guide management (e.g., complex infections where broad detection could affect therapy).

mNGS provides comprehensive detection and has higher pooled AUC for pulmonary infections; consider when results would change treatment.

Immunocompromised or complex cases: In immunocompromised patients or other complex cases (e.g., unclear etiology despite standard testing), mNGS or targeted molecular testing may be considered.

Not Covered / Exclusions

Multiplex respiratory pathogen panels that include six or more targets and are performed in outpatient settings are not covered because they are considered unproven and not medically necessary for routine outpatient care.

Routine use of multiplex panels to test for noninfluenza viral pathogens in average‑risk adult outpatients is not supported by current evidence. The ATS guideline suggests against routine outpatient testing for noninfluenza viruses, and outpatient data indicate limited changes in management from noninfluenza detections, making routine multiplex testing for these patients not covered.

Coding and Procedure Codes

Multiplex panel HCPCS/PLA codes (examples)HCPCS

0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.

Additional HCPCS/CPT codesmixed

0556U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0563U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
0564U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

FDA product codes referencedmixed

No codes listed

Panel target count threshold

ThresholdPanels of 6 or more respiratory targets in the outpatient setting are considered unproven and not medically necessary.

Positive/Negative agreement performance

Positive agreementReported positive agreement across targets ranges from 16.7% to 100%.

Negative agreementReported negative agreement for multiplex panels generally exceeds 90%.

Interpretation notePerformance varies by target and specimen type; limited sensitivity for some targets means negative results cannot reliably exclude infection.

Provider Actions, Prior Authorization, and Documentation

Denial Risk

Denial risk for large outpatient panels

Prior authorization and medical necessity review may apply for multiplex respiratory pathogen panels. Outpatient respiratory pathogen panels that include six or more targets are considered not medically necessary and may be denied.

Outpatient panels with ≥6 targets: Not medically necessary — may be denied.
Prior authorization/medical necessity review may be required for large-panel codes.

Prior Authorization

Prior authorization depends on benefit plan

Benefit plan coverage and prior authorization requirements vary by member plan. Verify the member's specific benefit plan and any applicable reimbursement policy before ordering testing.

Check member plan and reimbursement policy prior to testing.

Ordering Requirements and Operational Notes

Documentation Required

Ordering requirements — point‑of‑care syndromic testing context

Point‑of‑care syndromic testing has been studied when devices are run by trained staff in urgent care/clinic settings; targeted testing for influenza, RSV, or SARS‑CoV‑2 is often preferred before broad panels in outpatient contexts.

Meltzer et al. (2024) studied on‑site BioFire RP‑EZ testing performed by trained research staff with improved time to results and diagnostic confidence.
Beal et al. (2020) evaluated RP‑EZ use in outpatient pediatric clinics and informed ordering practice considerations.

Step Therapy

Ordering requirements — who should order

Order multiplex panel testing primarily through clinicians managing hospitalized, high‑risk, or pediatric patients; reserve outpatient testing for patients with severe presentations or high risk for complications.

ASM and IDSA guidance support multiplex testing for hospitalized/ICU, immunocompromised, transplant, hematology/oncology, and certain pediatric patients.

Frequency Limits

Frequency limits

Frequency limitsNot specified in this section of the document.

ImplicationNo per-patient testing interval or repeat-testing cadence is defined in the policy text provided.

Frequency limits (placeholder)

Placeholder entryNo frequency limit specified — retain for authoring fallback and plan-specific verification.

ActionVerify benefit-plan specific frequency or prior authorization rules when ordering.

Definitions and Background

Molecular assays—including reverse transcription PCR and other nucleic acid amplification tests—and metagenomic next‑generation sequencing detect microbial nucleic acids in respiratory specimens. Detection reflects nucleic acid presence and does not always indicate viable or replicating organisms; interpretation is affected by prolonged shedding, coinfection, and variable analytic performance across targets, so clinical correlation is required.

Multiplex RT-PCR (definition)

DefinitionMultiplex RT-PCR: reverse transcription–polymerase chain reaction assays that identify predefined microbial genetic material (RNA or nucleic acids) in respiratory specimens, detecting multiple targets in a single test.

Typical useUsed to rapidly test one specimen for several respiratory pathogens with high analytical accuracy.

LimitationsDetection does not confirm viable pathogen or active replication; clinical correlation required.

mNGS (definition)

OpenPayer

Respiratory Pathogen Nucleic Acid Detection Testing (for New Mexico Only)